Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McIntyre

Showing results (211-220 of 235) with videos related to

Pageof 24
Sort By:
Gastroenterology|September 8, 2014
The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in miceTinaMarie Lieu, Gihan Jayaweera, Peishen Zhao, et al.
Vaccine: X|March 8, 2021
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal <i>Haemophilus influenzae</i> protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAmanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 16, 2021
Serotonin-induced vascular permeability is mediated by transient receptor potential vanilloid 4 in the airways and upper gastrointestinal tract of miceJeffri S Retamal, Megan S Grace, Larissa K Dill, et al.
BMJ Open|May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trialVictor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
Australian and New Zealand Journal of Public Health|July 30, 2023
Ear health and hearing in urban Aboriginal childrenJack DeLacy, Leonie Burgess, Mandy Cutmore, et al.
Vaccine|September 15, 2007
Vaccine preventable diseases in indigenous populations - International perspectives. Satellite Symposium of the 5th International Symposium on Pneumococci and Pneumococcal Diseases, April 2006, Alice Springs, AustraliaRob Menzies, Peter McIntyre, Ray Reid, et al.
The Journal of Biological Chemistry|August 14, 2014
Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4Peishen Zhao, TinaMarie Lieu, Nicholas Barlow, et al.
Thorax|January 28, 2021
Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in AustraliaRoxanne Strachan, Nusrat Homaira, Sean Beggs, et al.
BMJ Open|June 23, 2019
'Links2HealthierBubs' cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian womenMohinder Sarna, Ross Andrews, Hannah Moore, et al.
BMC Medical Informatics and Decision Making|October 8, 2024
Forecasting severe respiratory disease hospitalizations using machine learning algorithmsSteffen Albrecht, David Broderick, Katharina Dost, et al.
Pageof 24

Showing results (211-220 of 235) with videos related to

Sort By:
Pageof 24
Gastroenterology|September 8, 2014
The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in miceTinaMarie Lieu, Gihan Jayaweera, Peishen Zhao, et al.
Vaccine: X|March 8, 2021
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal <i>Haemophilus influenzae</i> protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAmanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 16, 2021
Serotonin-induced vascular permeability is mediated by transient receptor potential vanilloid 4 in the airways and upper gastrointestinal tract of miceJeffri S Retamal, Megan S Grace, Larissa K Dill, et al.
BMJ Open|May 26, 2020
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trialVictor M Oguoma, Nicole Wilson, Kim Mulholland, et al.
Australian and New Zealand Journal of Public Health|July 30, 2023
Ear health and hearing in urban Aboriginal childrenJack DeLacy, Leonie Burgess, Mandy Cutmore, et al.
Vaccine|September 15, 2007
Vaccine preventable diseases in indigenous populations - International perspectives. Satellite Symposium of the 5th International Symposium on Pneumococci and Pneumococcal Diseases, April 2006, Alice Springs, AustraliaRob Menzies, Peter McIntyre, Ray Reid, et al.
The Journal of Biological Chemistry|August 14, 2014
Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4Peishen Zhao, TinaMarie Lieu, Nicholas Barlow, et al.
Thorax|January 28, 2021
Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in AustraliaRoxanne Strachan, Nusrat Homaira, Sean Beggs, et al.
BMJ Open|June 23, 2019
'Links2HealthierBubs' cohort study: protocol for a record linkage study on the safety, uptake and effectiveness of influenza and pertussis vaccines among pregnant Australian womenMohinder Sarna, Ross Andrews, Hannah Moore, et al.
BMC Medical Informatics and Decision Making|October 8, 2024
Forecasting severe respiratory disease hospitalizations using machine learning algorithmsSteffen Albrecht, David Broderick, Katharina Dost, et al.
Pageof 24